Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept for aGvHD Prevention in Unrelated Donor HSCT
NCT01012492Phase 2
Key facts
- Status
- Completed
- Start
- Nov 2009
- Primary completion
- Nov 2012
- Countries
- 1
- Sponsor
- Boston Children's Hospital
- Drugs
- abatacept
- Conditions
- graft-versus-host disease (GVHD)
01
Overview
Phase 2, open-label trial of abatacept in graft-versus-host disease (GVHD), sponsored by Boston Children's Hospital. Primary endpoint: Percentage of Participants With Grade III-IV Acute GVHD by Day 100. Started Nov 2009; status: completed.
02
Design
- Study design
- Non-randomizedOpen-labelSingle group
03
Who it enrols
Patients aged 12 or older with high-risk AML, ALL, or MDS undergoing their first unrelated donor HSCT with a Karnofsky/Lansky score of at least 80.
04
Endpoints
Primary
Percentage of Participants With Grade III-IV Acute GVHD by Day 100
Beyond the preview
Go deeper on NCT01012492.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01012492.